Novo Nordisk A/S $NVO Holdings Decreased by DSM Capital Partners LLC

Key Points

• DSM Capital Partners LLC reduced its holdings in Novo Nordisk A/S by 14.4% in the second quarter, now owning approximately 1.8% of the company, valued at $121,543,000.
• Novo Nordisk A/S reported earnings per share of $0.97 for the latest quarter, exceeding analysts' expectations of $0.93, while total revenue for the period was $11.69 billion.
• The company recently cut its dividend to $0.4119, representing a yield of 240.0%, with a payout ratio of 22.53%.

DSM Capital Partners LLC trimmed its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 14.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,760,978 shares of the company's stock after selling 295,609 shares during the quarter. Novo Nordisk A/S makes up approximately 1.8% of DSM Capital Partners LLC's holdings, making the stock its 18th largest position. DSM Capital Partners LLC's holdings in Novo Nordisk A/S were worth $121,543,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in NVO. Copeland Capital Management LLC boosted its position in Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after purchasing an additional 255 shares during the period. North Capital Inc. bought a new stake in Novo Nordisk A/S in the first quarter valued at $27,000. Stone House Investment Management LLC bought a new stake in Novo Nordisk A/S in the first quarter valued at $30,000. Disciplina Capital Management LLC lifted its stake in Novo Nordisk A/S by 162.3% in the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock valued at $33,000 after buying an additional 297 shares during the last quarter. Finally, Spirit of America Management Corp NY bought a new stake in Novo Nordisk A/S in the first quarter valued at $35,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Trading Down 3.0%

Shares of NVO stock opened at $56.95 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $120.56. The stock has a fifty day moving average of $55.44 and a two-hundred day moving average of $63.22. The firm has a market capitalization of $254.27 billion, a PE ratio of 15.64, a price-to-earnings-growth ratio of 2.65 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. The company had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were issued a $0.4119 dividend. The ex-dividend date was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S's dividend payout ratio is 22.53%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on NVO. BNP Paribas Exane upgraded Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 target price on the stock in a research note on Wednesday, August 13th. Wall Street Zen cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Sanford C. Bernstein upgraded Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, September 9th. Berenberg Bank upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Wednesday, September 17th. Finally, Zacks Research upgraded Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Monday, September 29th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $77.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.